CGEM logo

CULLINAN THERAPEUTICS INC

CGEMNASDAQ
🏆 #2539 by market capEarnings Nov 4US Equity
$245.50▲ $8.37 (+3.41%)
Simulated price
🔔
Track CGEM
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 3.4%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$910M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
76
Good
No chart data available for CGEM.

Trading Snapshot

Day Range
$242.39 – $248.97
52-Week Range
$5.68 – $23.19
Volume
$3.68B
Avg Volume
$2.77B
Shares Outstanding
61.5M
Next Earnings
Oct 30, 2026

Fundamentals Snapshot

Annual Revenue
$64M
Last Q Revenue
$17M
P/E Ratio
-4.4
P/S Ratio
0.0x
EPS (TTM)
$-3.33
Dividend Yield
0.00%
Dilution (1yr)
+1.1%

Why Investors Own CGEM

  • ✓High-growth profile — revenue up +53.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 46% gross margin and 15% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CGEM logo

CULLINAN THERAPEUTICS INC

CGEM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$242M▲ +22.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$176M▲ +21.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
59.2M▲ +1.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$86M▲ +$5M YoY
StockOtter · stockotter.space

About CULLINAN THERAPEUTICS INC

Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Price Target

ⓘ
Average Target
$259.15
▲ +5.6% Upside
High Target$299.51
Low Target$229.11
Based on 39 analysts

Latest News & Updates

🚀
Barron’s·2h ago

CULLINAN THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift CGEM price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

CULLINAN THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.